Abstract
Colorectal cancer is a serious complication of inflammatory bowel disease. Given this fact, it is necessary to examine the opportunities for current and future approaches to colorectal cancer prevention. The value of surveillance colonoscopy and chemoprevention of colorectal cancer with 5′-aminosalicylic acid has been evaluated in the recent literature. The current state of knowledge in the epidemiology of and new approaches to the prevention of cancer and dysplasia in inflammatory bowel disease were reviewed. It is concluded that there is significant preclinical and clinical evidence to suggest that 5-aminosalicylate drugs reduce the risk of colorectal neoplasia. However, the minimal dosage to achieve this chemopreventive effect remains unclear. There is also indirect evidence to suggest that surveillance colonoscopy is beneficial for patients with inflammatory bowel disease, particularly in those with long-standing pancolitis or primary sclerosing cholangitis-associated inflammatory bowel disease. However, definitive proof from prospective clinical trials is not available.
Journal Section:
Review
References
1.
Ekbom A, Helmick C, Zack M, Adami HO: Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990;336:357–359.
2.
Langholz E, Munkholm P, Davidsen M, Binder V: Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444–1451.
[PubMed]
3.
Choi PM, Zelig MP: Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994;35:950–954.
[PubMed]
4.
Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN: Mortality in ulcerative colitis. Gastroenterology 1982;83:36–43.
[PubMed]
5.
Ekbom A, Helmick C, Zack M, Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228–1233.
[PubMed]
6.
Lennard-Jones JE: Cancer risk in ulcerative colitis: surveillance or surgery. Br J Surg 1985;72(suppl):84–86.
7.
Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, Lofberg R, Brostrom O, Hellers G: Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988;29:206–217.
[PubMed]
8.
Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–535.
9.
Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451–459.
10.
Broome U, Lofberg R, Veress B, Eriksson LS: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404–1408.
11.
Ullman T, Croog V, Harpaz N, Itzkowitz S, Kornbluth A: Preventing neoplastic progression in ulcerative colitis: role of mesalamine (abstract). Gastroenterology 2003;124(suppl 1):A242.
12.
Munkholm P, Langholz E, Davidsen M, Binder V: Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993;105:1716–1723.
[PubMed]
13.
Gilat T, Fireman Z, Grossman A, Hacohen D, Kadish U, Ron E, Rozen P, Lilos P: Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 1988;94:870–877.
[PubMed]
14.
Winther KV, Jess T, Langholz E, Munkholm P, Binder V: Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088–1095.
15.
Munkholm P: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(suppl 2):1–5.
16.
Sutherland L, Roth D, Beck P, May G, Makiyama K: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002;CD000544.
17.
Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95:3452–3457.
[PubMed]
18.
Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163–1174.
[PubMed]
19.
Kaiser GC, Yan F, Polk DB: Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999;116:602–609.
20.
Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005;201:1205–1215.
21.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285–296.
22.
Reinacher-Schick A, Seidensticker F, Petrasch S, Reiser M, Philippou S, Theegarten D, Freitag G, Schmiegel W: Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000;32:245–254.
23.
Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W: Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003;24:443–451.
24.
Schmiegel W, Pox CP, Reiser M: Effect of 5-aminosalicylate (5-ASA) on the recurrence rate of sporadic colorectal adenomas (abstract). Gastroenterology 2004;126(suppl 2):A452.
25.
Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO: Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117–120.
[PubMed]
26.
Moody GA, Jayanthi V, Probert CS, Mac KH, Mayberry JF: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179–1183.
[PubMed]
27.
Eaden J: The data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(suppl 2):15–21.
28.
Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145–153.
29.
Rubin DT, Djordjevic A, Huo D, Yadron N, Hanauer SB: Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis (abstract). Gastroenterology 2003;123(suppl 1):A36.
30.
van Staa TP, Card T, Logan RF, Leufkens HG: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54:1573–1578.
31.
Bernstein CN, Blanchard JF, Metge C, Yogendran M: Does the use of 5 aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784–2788.
32.
Velayos FS, Terdiman JP, Walsh JM: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk. A systematic review and meta-analysis of observational studies. Am J Gastroenterol 2005;100:1345–1353.
33.
Lindberg BU, Broome U, Persson B: Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001;44: 77–85.
34.
Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A: The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29–32.
35.
Itzkowitz SH: Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:1133–1144.
36.
Kane SV, Cohen RD, Aikens JE, Hanauer SB: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929–2933.
37.
Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89–95.
[PubMed]
38.
Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889–893.
39.
Hawk ET, Viner JL: Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med 2001;134:158–160.
[PubMed]
40.
Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P: Phoenix and Tucson Gastroenterologist Networks. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97:846–853.
[PubMed]
41.
Matula S, Croog V, Itzkowitz S, Harpaz N, Ullman T: The effect of 6-mercaptopurine on progression to colorectal neoplasia in ulcerative colitis (abstract). Gastroenterology 2004;126 (suppl 2):A137.
42.
Winawer SJ, St John DJ, Bond JH, Rozen P, Burt RW, Waye JD, Kronborg O, O’Brien MJ, Bishop DT, Kurtz RC: Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer. Bull World Health Organ 1995;73:7–10.
[PubMed]
43.
Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, Saslow D, Cokkinides V, Eyre H: American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 2001;51:38–75.
[PubMed]
44.
Itzkowitz SH, Present DH, Crohn’s and Colitis Foundation of America Colon Cancer in IBD Study Group: Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314–321.
45.
Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C: Colorectal cancer screening and surveillance: clinical guidelines and rationale – update based on new evidence. Gastroenterology 2003;124:544–560.
[PubMed]
46.
Bernstein CN, Shanahan F, Weinstein WM: Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71–74.
47.
Loftus EV Jr: Does monitoring prevent cancer in inflammatory bowel disease? J Clin Gastroenterol 2003;36(suppl 5):79–83.
48.
Bernstein CN: Challenges in designing a randomized trial of surveillance colonoscopy in IBD. Inflamm Bowel Dis 1998;4:132–141.
[PubMed]
49.
Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML, Haggitt RC: Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993;105:418–424.
[PubMed]
50.
Connell WR, Talbot IC, Harpaz N, Britto N, Wilkinson KH, Kamm MA, Lennard-Jones JE: Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994;35:1419–1423.
[PubMed]
51.
Giardiello FM, Gurbuz AK, Bayless TM, Yardley JH: Colorectal cancer in ulcerative colitis: effect of a cancer prevention strategy on survival (abstract). Gastroenterology 1993;104:A705.
52.
Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A: Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998;42:711–714.
[PubMed]
53.
Lindberg B, Persson B, Veress B, Ingelman-Sundberg H, Granqvist S: Twenty years’ colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand J Gastroenterol 1996;31:1195–1204.
[PubMed]
54.
Gorfine SR, Bauer JJ, Harris MT, Kreel I: Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted? Dis Colon Rectum 2000;43:1575–1581.
55.
Ullman TA, Loftus EV Jr, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ: The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002;97:922–927.
56.
Provenzale D, Kowdley KV, Arora S, Wong JB: Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995;109:1188–1196.
57.
Provenzale D, Wong JB, Onken JE, Lipscomb J: Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 1998;93:872–880.
58.
Engelsgjerd M, Farraye FA, Odze RD: Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999;117:1288–1294.
59.
Rubin PH, Friedman S, Harpaz N, Goldstein E, Weiser J, Schiller J, Waye JD, Present DH: Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295–1300.
60.
Odze RD, Farraye FA, Hecht JL, Hornick JL: Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2:534–541.
61.
Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF: Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880–888.
62.
Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC: Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53:256–260.
© 2006 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2006
You do not currently have access to this content.
